PT Kalbe Farma Tbk. (PTKFY)
OTCMKTS
· Delayed Price · Currency is USD
19.50
0.00 (0.00%)
Jul 7, 2025, 4:00 PM EDT
PT Kalbe Farma Tbk. Revenue
PT Kalbe Farma Tbk. had revenue of 8.85T IDR in the quarter ending March 31, 2025, with 5.77% growth. This brings the company's revenue in the last twelve months to 33.11T, up 7.00% year-over-year. In the year 2024, PT Kalbe Farma Tbk. had annual revenue of 32.63T with 7.16% growth.
Revenue (ttm)
33.11T IDR
Revenue Growth
+7.00%
P/S Ratio
2.11
Revenue / Employee
2.57B IDR
Employees
12,903
Market Cap
4.21B USD
Revenue Chart
* This company reports financials in IDR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.63T | 2,178.64B | 7.16% |
| Dec 31, 2023 | 30.45T | 1,515.63B | 5.24% |
| Dec 31, 2022 | 28.93T | 2,672.31B | 10.18% |
| Dec 31, 2021 | 26.26T | 3,148.54B | 13.62% |
| Dec 31, 2020 | 23.11T | 479.18B | 2.12% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 84.04M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |